Alliance Group to invest $800,000 at its Mataura plant
The new facility at the plant will collect and process adult bovine blood into serum for blood products, which are used in the development of vaccines, cancer treatments, and drugs to treat
neurodegenerative, haematological and endocrine disorders.
Demand from the pharmaceutical industry for New Zealand blood products has increased significantly due to the country’s disease-free status and world-leading agricultural systems.
David Surveyor, chief executive of Alliance Group, said blood products can create value for the cooperative’s shareholders.
“Our strategy is maximising revenue, diversifying our products and strengthening our market channels," said Mr. Surveyor. “This investment is another example of how we are developing opportunities to capture more market value for our shareholders.”
Alliance Group is a co-operative owned by approximately 5,000 farmer shareholders and exports lamb, beef, venison and co-products to customers in more than 65 countries.
ASF incidence in Germany has remained at an elevated level since the beginning of the year. Accor...
As part of MLA’s involvement in the Sydney Royal Easter Show (SRES), each year the Australi...
Expanding its scope, the 2025 edition integrates unprecedented analyses of the global value chain...
